The Montgomery County life sciences company raised $7 million through private financing.

The Hatfield, Pa. company plans to use the bulk of funding to advance its 3DNA nanotechnology platform for targeted drug delivery, writes John George for the Philadelphia Business Journal.

[uam_ad id=”54865″]

The 3DNA platform — which involves the creation of a nanoscale scaffold made from proprietary, synthetic DNA formed in a flexible, branched structure — is designed to improve the ability of a drugs to be transported across physiological barriers and into cells to bind to their intended targets.

“The progress Genisphere has made with its academic and commercial partners, and on its own with contract research organizations, supported this raise,” said Tom Bliss, the company’s CEO.

Bliss said the funds will allow the company to build its licensing business, whereby it creates 3DNA-enabled therapeutics that “demonstrate the clear advantage of combining disease-site-specific targeting with a potent payload to improve therapeutic index.”

Last year, Genisphere signed its first major Big Pharma partnership, a collaborative research and option to license agreement, with MedImmune, the global biologics research and development arm of AstraZeneca (NYSE: AZN). Under the partnership, MedImmune and Genisphere will work together to develop novel nanoparticles using Genisphere’s 3DNA drug delivery platform in up to six MedImmune oncology molecules.

To read the complete story click here. 

[uam_ad id=”54875″]